|
H6: a review of the manufacturing records for the device verified that the lot met all pre-release specifications.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
It was reported to gore that on (b)(6) 2026, the patient underwent endovascular treatment for a thoracic aortic aneurysm using the gore® dryseal flex introducer sheath as an accessory.Resistance was encountered during the insertion of the 24fr sheath.After deployment of the stent graft and removal of the sheath, a dissection was identified around the aortic bifurcation and the right common iliac artery.Additionally, diminished palpability of pulses in the right lower extremity and decreased doppler signals were noted; however, the procedure was completed with follow-up observation.The patient tolerated the procedure.
|